Ezetimibe no cancer risk
Treatment with ezetimibe does not increase a patient's risk of cancer, according to a major study of its use when prescribed in combination with a statin.
A previous study – the SEAS trial – had found ezetimibe was associated with an increase in new-onset cancers. But researchers from the University of Oxford analysed data from three trials, including SEAS, on 22,490 patients prescribed three different dose combinations of ezetimibe and simvastatin for a total mean follow-up period of 7.8 years.
The risk of cancer with ezetimibe was 0.96, indicating no effect on cancer incidence.
N Engl J Med 2008:359.